FORMULATION ARTICLES
-
![double stranded circular rna-GettyImages-2220593312]( "Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA Therapeutics")
Location Matters: How The Nuclear Geography Of circRNAs Could Shape The Future Of RNA TherapeuticsCircRNA location may be as important as its sequence. Discover how nuclear organization could influence the next generation of RNA therapeutics.
-
![drug delivery, nanotechnology technology-GettyImages-1337413453]( "Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic Discovery")
Building The RNA Knowledge Graph: How Better Annotation Is Accelerating Therapeutic DiscoveryAs RNA therapeutics grow more complex, better biological annotation is becoming the foundation for AI-driven discovery, target selection, and smarter drug development.
-
![Small interfering RNA, sirna, mrna, crispr-GettyImages-1409578453]( "Building A Self-Driving Lab For LNP Development")
Building A Self-Driving Lab For LNP DevelopmentWith commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.
-
![Cellular gas photo]( "Beyond Vaccines: Can RNA Sense Gases?")
Beyond Vaccines: Can RNA Sense Gases?Could RNA sense its environment? A new hypothesis explores how RNA may detect temperature and gases, inspiring smarter, adaptive RNA therapeutics.
-
![technology and science-GettyImages-1440932538]( "Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA Fate")
Decoding RNA's Circular Decisions: How HNRNPD Shapes circRNA Biogenesis And RNA FateHow do cells decide between circular and linear RNA? New insights into HNRNPD reveal mechanisms that could improve the design of future circRNA therapeutics.
-
![DNA target nanodrugs-GettyImages-1405926704]( "Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient Disease")
Beyond Gene Silencing: Harnessing Regulatory RNAs To Increase Gene Expression In Haploinsufficient DiseaseCan RNA therapeutics increase — not silence — gene expression? Regulatory RNA-targeting ASOs may redefine treatment for haploinsufficient diseases.
FORMULATION VIDEOS
In this segment, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, discuss which ongoing industry efforts to improve LNPs and the RNA/mRNA cargo they're watching closely that could help the RNA industry move beyond hepatic delivery.
NxGen™ microfluidic technology enables controlled and precise assembly of high-quality, uniform LNPs, ensuring reproducible scale-up of RNA-LNPs while maximizing drug loading and particle quality.
The clinical promise of mRNA therapeutics and vaccines is clear, but compared to monoclonal antibodies or viral vectors, their novelty also brings new challenges to the manufacturing process.
The quest for the “extra-hepatic GalNAc” is on. In this Advancing RNA Live clip, NanoVation Therapeutics’ Dominik Witzigmann and Stealth Co’s John Zuris walk through some of the most popular targeting ligand choices being explored in the RNA delivery space today, sharing which they believe will be the most game-changing.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-533059254-rna-dna-strand-light]( "Scalable, Sustainable Support For Next‑Gen Primer Systems")
Explore how an optimized solid‑support design enables higher synthesis scales, steadier pressures, and lower solvent use while preserving yield and purity across diverse oligonucleotide lengths.
-
![GettyImages-2190227882-male-scientist-lab]( "LNP-Mediated Cell Transfection In Bioreactors Across Workflows")
Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.
-
![GettyImages-2270198779-blue-lipid-nanoparticle-system-delivery]( "Towards A Universal LNP Platform For Multiplex Engineering")
Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
-
![nanoparticles-drug molecule-GettyImages-1428647836]( "Accelerate LNP Manufacturing With Automated Process Development")
Manual LNP formulation introduces process variability that threatens particle quality and yield. As programs scale toward clinical production, maintaining strict control over CQAs becomes essential.
-
![Crispr gene editing-GettyImages-1139760176]( "CRISPR 101 - Your Guide To Understanding CRISPR")
Review the fundamentals of CRISPR technology, development, and its use to manipulate genes in different ways, such as altering their nucleotide sequences or changing their expression.
-
![iStock-1140779660-drug-development-lab]( "Enabling Continuous Manufacturing For CAR-T And LNP-Based Therapies")
Breakthrough therapies are challenged by complex, batch-based manufacturing. A novel, integrated system enables continuous processing, improving consistency and reducing manual handling for advanced modalities.
-
![Lipid Nanoparticle mRNA Vaccine GettyImages-1418152448]( "Fit-For-Purpose Lipids Can Accelerate, Scale, And Improve RNA-LNP Drugs")
Emerging biotech companies are investing in novel delivery capabilities to address different modalities' needs and extra-hepatic delivery. Explore steps to accelerate commercial nanomedicine delivery.
